THE BCL-2 ANTAGONIST ABT-737 IS HIGHLY EFFECTIVE ON PRIMARY ACUTE LYMPHOBLASTIC LEUKEMIA CELLS

被引：0
|
作者：
Decandia, S. [1 ]
Ricciardi, M. R. [1 ]
Santinelli, S. [1 ]
De Cave, F. [1 ]
Gregorj, C. [1 ]
Bergamo, P. [2 ]
Libotte, F. [1 ]
Vitale, A. [1 ]
Petrucci, M. T.
Milella, M. [1 ,2 ]
Foa, R. [1 ]
Tafuri, A. [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy
[2] Regina Elena Inst Canc Res, Med Oncol A, Rome, Italy
来源：
HAEMATOLOGICA | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P109
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [31] ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases docetaxel-mediated apoptosis in human prostate cancer cells
    Parrondo, Ricardo
    de las Pozas, Alicia
    Reiner, Teresita
    Perez-Stable, Carlos
    CANCER RESEARCH, 2011, 71
  • [32] ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
    Parrondo, Ricardo
    de las Pozas, Alicia
    Reiner, Teresita
    Perez-Stable, Carlos
    PEERJ, 2013, 1
  • [33] Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
    Merino, Delphine
    Khaw, Seong L.
    Glaser, Stefan P.
    Anderson, Daniel J.
    Belmont, Lisa D.
    Wong, Chihunt
    Yue, Peng
    Robati, Mikara
    Phipson, Belinda
    Fairlie, Walter D.
    Lee, Erinna F.
    Campbell, Kirsteen J.
    Vandenberg, Cassandra J.
    Cory, Suzanne
    Roberts, Andrew W.
    Ludlam, Mary J. C.
    Huang, David C. S.
    Bouillet, Philippe
    BLOOD, 2012, 119 (24) : 5807 - 5816
  • [34] ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells
    M P Kline
    S V Rajkumar
    M M Timm
    T K Kimlinger
    J L Haug
    J A Lust
    P R Greipp
    S Kumar
    Leukemia, 2007, 21 : 1549 - 1560
  • [35] The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs
    High, Laura M.
    Szymanska, Barbara
    Wilczynska-Kalak, Urszula
    Barber, Nicole
    O'Brien, Rosemary
    Khaw, Seong Lin
    Vikstrom, Ingela B.
    Roberts, Andrew W.
    Lock, Richard B.
    MOLECULAR PHARMACOLOGY, 2010, 77 (03) : 483 - 494
  • [36] ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells
    Kline, M. P.
    Rajkumar, S. V.
    Timm, M. M.
    Kimlinger, T. K.
    Haug, J. L.
    Lust, J. A.
    Greipp, P. R.
    Kumar, S.
    LEUKEMIA, 2007, 21 (07) : 1549 - 1560
  • [37] The BH3 mimetic, ABT-737, is effective against Bcl-2 overexpressing lymphoid tumors.
    Mason, Kylie D.
    Vandenberg, Cassandra J.
    van Delft, Mark F.
    Wei, Andrew H.
    Cory, Suzanne
    Clare, Scott L.
    Roberts, Andrew W.
    Huang, David C. S.
    BLOOD, 2006, 108 (11) : 248A - 248A
  • [38] Cytotoxicity, Drug Combinability, and Biological Correlates of ABT-737 Against Acute Lymphoblastic Leukemia Cells With MLL Rearrangement
    Jayanthan, Aarthi
    Incoronato, Andrea
    Singh, Anjali
    Blackmore, Christopher
    Bernoux, Delphine
    Lewis, Victor
    Stam, Ronald
    Whitlock, James A.
    Narendran, Aru
    PEDIATRIC BLOOD & CANCER, 2011, 56 (03) : 353 - 360
  • [39] Teaching an old drug new tricks Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737
    Krystal, Geoffrey W.
    CANCER BIOLOGY & THERAPY, 2010, 10 (09) : 934 - 936
  • [40] Therapeutic Efficacy of ABT-737, a Bcl-2 Inhibitor, in a Canine Melanoma Cell Line
    Uwano, Mai
    Kano, Rui
    Maruyama, Haruhiko
    Hasegawa, Atsuhiko
    Kamata, Hiroshi
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2012, 74 (06): : 783 - 785
12345